The drugmaker in 2017 made itself the center of controversy with a patent licensing tactic that involved a Native American tribe, and it now faces competitive threats to top sellers Restasis and Botox. Allergan's latest announcement came along with news that former Celgene CEO Bob Hugin is joining the company's board after a failed run for a U.S. Senate seat. Hugin, an influential pharma executive, is the sixth new director at Allergan since 2017.